Answers are grounded in this paper and cite their sources.
INTRODUCTION: , respectively. METHODS: who had received placebo in REPRISE and began tolvaptan in OLE. The second comprised subjects who had received tolvaptan in REPRISE and were matched to REPRISE placebo-treated subjects for REPRISE baseline characteristics. Annualized eGFR slopes in REPRISE versus OLE were compared within the REPRISE placebo (i.e., placebo vs. tolvaptan treatment) and tolvaptan (i.e., 2 periods of tolvaptan treatment) subsets. In REPRISE tolvaptan subjects who continued tolvaptan in OLE, treatment effect was maintained (no difference between mean annualized eGFR slopes). CONCLUSION: .
No takes yet. Share an insight, caveat, or question.
Torres et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: